Targeting CDK2 in CDK4/6 inhibitor-resistant HR-positive/HER2-negative breast cancer
Active Grant Awarded Last action
- Award ID
- R01CA316243
- Recipient
-
The General Hospital Corporation UEI FLJ7DQKLL226
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $660,843
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 4% complete
- Place of performance
- Boston, MA 02114, USA
Award details come from USAspending.gov.
About this award
The National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services, awarded Grant R01CA316243 to The General Hospital Corporation, doing business as Massachusetts General Hospital, for $660,843 on September 9, 2026. The award falls under Assistance Listing 93.395, Cancer Treatment Research.
The funded project, "Targeting CDK2 in CDK4/6 Inhibitor-Resistant HR-Positive/HER2-Negative Breast Cancer," examines next-generation selective CDK2 inhibitors in HR+/HER2- breast cancer that has become resistant to CDK4/6 inhibitors. The project addresses four questions: how genetic background and treatment history shape CDK2 inhibitor mechanisms of action, which pharmacodynamic markers reliably capture CDK2 activity, which combination strategies most effectively enhance CDK2 inhibitor efficacy in CDK4/6 inhibitor-resistant models, and what mechanisms drive resistance to CDK2 inhibitors. The investigators hypothesize that combining CDK2 and CDK4/6 inhibitors produces synergy by concurrently targeting the G1/S and G2/M checkpoints. The project builds on preliminary data for PF-07104091 monotherapy and on patient-derived cell line studies.
The award runs from its September 9, 2026 award date to an ultimate completion date of August 31, 2031. Place of performance is Boston, Massachusetts 02114, USA. The assistance type is grant.
Description
- Abstract
- Hormone receptor-positive, human epidermal growth factor receptor-2-negative (HR+/HER2-) breast cancer (BC) represents 65-75% of all new cases, with a sharp decline in 5-year survival for metastatic (MBC) disease. The current standard of care for HR+/HER2- MBC combines hormonal therapy (HT) with cyclin-dependent kinase 4/6 inhibitors (CDK4/6I), which block retinoblastoma (RB) phosphorylation, reinforce cell cycle arrest, and suppress tumor growth. Despite substantial benefit, nearly all patients eventually develop resistance, underscoring the need for new targeted therapies. Resistance to CDK4/6I is genetically diverse, making single approaches unlikely to be effective across all tumors. Since CDK2 acts downstream of CDK4/6 to inactivate RB, next-generation selective CDK2 inhibitors (CDK2I) with improved tolerability represent a promising therapeutic strategy, and several are currently tested in early-phase clinical trials. Our preliminary data with PF-07104091 CDK2I monotherapy revealed clinical benefit in a group of patients with CDK4/6I-resistant HR+/HER2- MBC, with efficacy independent of RB but associated with TP53 status. Complementary studies in patient-derived cell lines (PDCLS) demonstrated that CDK2I acts independently of RB, reducing DNA replication, inducing DNA damage, and triggering apoptosis. These observations raise four fundamental questions: (1) how do genetic background and treatment history shape CDK2I mechanisms of action? (2) what pharmacodynamic markers reliably capture CDK2 activity? (3) which combination strategies most effectively enhance CDK2I efficacy, particularly in CDK4/6I-resistant models? And (4) what mechanisms drive resistance to CDK2I? The distinct mechanisms of CDK2I and CDK4/6I in HR+/HER2- MBC suggest potential synergy through concurrent targeting of the G1/S and G2/M checkpoints. We hypothesize that CDK2I-CDK4/6I combinations will outperform single agents, with benefit shaped by the stage of CDK4/6I treatment and RB1 or TP53 status. Leveraging our unique PDCLS panel and integrated clinical-translational expertise, we propose to develop a comprehensive framework to understand CDK2 inhibition. Aim 1 will define the molecular mechanisms and pharmacodynamic markers of CDK2 inhibition using PDCLS and xenografts representing diverse genetic and treatment contexts, coupled with phosphoproteomic profiling. Human tumor xenografts in immunodeficient mice recapitulate key features of patient tumors and provide critical information on therapeutic efficacy and toxicity unavailable from in vitro models. Aim 2 will identify rational combination strategies, evaluating CDK2I in combination with CDK4/6I, selective CDK4I, endocrine therapy, or S-phase targeting chemotherapy, while delineating the roles of RB1 and TP53 in shaping response. Aim 3 will uncover mechanisms of CDK2I resistance and validate them in paired CDK2I-sensitive and -resistant models. Successful completion of these studies will inform ongoing clinical trials of selective CDK2 inhibitors and accelerate their translation into improved patient outcomes.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $660,843 |
Quick answers
Who received award R01CA316243?
R01CA316243 was awarded to The General Hospital Corporation by National Cancer Institute (National Institutes of Health) on September 9, 2026.
How much is award R01CA316243 worth?
$660,843 has been obligated on R01CA316243.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award